Mohan, M., Szabó, A., Narra, R. K., Skoog, C., Goff, A., Dhakal, B., Akhtar, O., Pasquini, M., Radhakrishnan, S., Rao, S., Malarkannan, S., Schinke, C., Rasche, L., D'Souza, A. (2025). Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.. Blood. https://doi.org/10.1182/blood-2025-5758